# Safety, Tolerability, and Pharmacokinetics of CSX-1004

> **NCT06005402** · PHASE1 · COMPLETED · sponsor: **Cessation Therapeutics, Inc.** · enrollment: 32 (actual)

## Conditions studied

- Opioid Overdose
- Opioid Use Disorder

## Interventions

- **BIOLOGICAL:** CSX-1004
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT06005402
- **Lead sponsor:** Cessation Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-08-01
- **Primary completion:** 2024-05-28
- **Final completion:** 2024-05-28
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2024-08-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06005402

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06005402, "Safety, Tolerability, and Pharmacokinetics of CSX-1004". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT06005402. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*